Clinical Pharmacogenetic Testing and Application: 2024 Updated Guidelines by the Korean Society for Laboratory Medicine

Overview

Journal Ann Lab Med

Specialty Pathology

Date 2024 Dec 16

PMID 39681357

Authors

John Hoon Rim

Young-Gon Kim

Sollip Kim

Rihwa Choi

Jee-Soo Lee

Seungman Park

Woochang Lee

Eun Young Song

Soo-Youn Lee

Sail Chun

Affiliations

Soon will be listed here.

Abstract

In the era of precision medicine, pharmacogenetics has substantial potential for addressing inter-individual variability in drug responses. Although pharmacogenetics has been a research focus for many years, resulting in the establishment of several formal guidelines, its clinical implementation remains limited to several gene-drug combinations in most countries, including Korea. The main causes of delayed implementation are technical challenges in genotyping and knowledge gaps among healthcare providers; therefore, clinical laboratories play a critical role in the timely implementation of pharmacogenetics. This paper presents an update of the Clinical Pharmacogenetic Testing and Application guidelines issued by the Korean Society for Laboratory Medicine and aims to provide the necessary information for clinical laboratories planning to implement or expand their pharmacogenetic testing. Current knowledge regarding nomenclature, gene-drug relationships, genotyping technologies, testing strategies, methods for clinically relevant information delivery, QC, and reimbursements has been curated and described in this guideline.

References

Cooper-DeHoff R, Niemi M, Ramsey L, Luzum J, Tarkiainen E, Straka R . The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022; 111(5):1007-1021. PMC: 9035072. DOI: 10.1002/cpt.2557. View

Twesigomwe D, Drogemoller B, Wright G, Adebamowo C, Agongo G, Boua P . Characterization of CYP2D6 Pharmacogenetic Variation in Sub-Saharan African Populations. Clin Pharmacol Ther. 2022; 113(3):643-659. PMC: 9957841. DOI: 10.1002/cpt.2749. View

Hinderer M, Boeker M, Wagner S, Lablans M, Newe S, Hulsemann J . Integrating clinical decision support systems for pharmacogenomic testing into clinical routine - a scoping review of designs of user-system interactions in recent system development. BMC Med Inform Decis Mak. 2017; 17(1):81. PMC: 5461630. DOI: 10.1186/s12911-017-0480-y. View

Morris S, Alsaidi A, Verbyla A, Cruz A, Macfarlane C, Bauer J . Cost Effectiveness of Pharmacogenetic Testing for Drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines: A Systematic Review. Clin Pharmacol Ther. 2022; 112(6):1318-1328. PMC: 9828439. DOI: 10.1002/cpt.2754. View

Birdwell K, Decker B, Barbarino J, Peterson J, Stein C, Sadee W . Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clin Pharmacol Ther. 2015; 98(1):19-24. PMC: 4481158. DOI: 10.1002/cpt.113. View

Kim J, Ceccarelli R, Lu C . Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000-2020). J Pers Med. 2021; 11(3). PMC: 8000585. DOI: 10.3390/jpm11030179. View

Lee C, Luzum J, Sangkuhl K, Gammal R, Sabatine M, Stein C . Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clin Pharmacol Ther. 2022; 112(5):959-967. PMC: 9287492. DOI: 10.1002/cpt.2526. View

Turner A, Nofziger C, Ramey B, Ly R, Bousman C, Agundez J . PharmVar Tutorial on CYP2D6 Structural Variation Testing and Recommendations on Reporting. Clin Pharmacol Ther. 2023; 114(6):1220-1237. PMC: 10840842. DOI: 10.1002/cpt.3044. View

Johnson J, Caudle K, Gong L, Whirl-Carrillo M, Stein C, Scott S . Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017; 102(3):397-404. PMC: 5546947. DOI: 10.1002/cpt.668. View

10.

Li B, Sangkuhl K, Whaley R, Woon M, Keat K, Whirl-Carrillo M . Frequencies of pharmacogenomic alleles across biogeographic groups in a large-scale biobank. Am J Hum Genet. 2023; 110(10):1628-1647. PMC: 10577080. DOI: 10.1016/j.ajhg.2023.09.001. View

11.

Rogers A, Mackenzie I, MacDonald T, Doney A . The PREPARE study: benefits of pharmacogenetic testing are unclear. Lancet. 2023; 401(10391):1850. DOI: 10.1016/S0140-6736(23)00853-X. View

12.

Li B, Sangkuhl K, Keat K, Whaley R, Woon M, Verma S . How to Run the Pharmacogenomics Clinical Annotation Tool (PharmCAT). Clin Pharmacol Ther. 2022; 113(5):1036-1047. PMC: 10121724. DOI: 10.1002/cpt.2790. View

13.

Kim S, Yun Y, Chae H, Cho H, Ji M, Kim I . Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines. Ann Lab Med. 2016; 37(2):180-193. PMC: 5204002. DOI: 10.3343/alm.2017.37.2.180. View

14.

Chenchula S, Atal S, Uppugunduri C . A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care. Pharmacogenomics J. 2024; 24(2):9. PMC: 10942860. DOI: 10.1038/s41397-024-00326-1. View

15.

Abdullah-Koolmees H, van Keulen A, Nijenhuis M, Deneer V . Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines. Front Pharmacol. 2021; 11:595219. PMC: 7868558. DOI: 10.3389/fphar.2020.595219. View

16.

Caudle K, Dunnenberger H, Freimuth R, Peterson J, Burlison J, Whirl-Carrillo M . Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 2016; 19(2):215-223. PMC: 5253119. DOI: 10.1038/gim.2016.87. View

17.

Hicks J, Sangkuhl K, Swen J, Ellingrod V, Muller D, Shimoda K . Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2016; 102(1):37-44. PMC: 5478479. DOI: 10.1002/cpt.597. View

18.

Whirl-Carrillo M, Huddart R, Gong L, Sangkuhl K, Thorn C, Whaley R . An Evidence-Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine. Clin Pharmacol Ther. 2021; 110(3):563-572. PMC: 8457105. DOI: 10.1002/cpt.2350. View

19.

Lunenburg C, van der Wouden C, Nijenhuis M, Crommentuijn-van Rhenen M, de Boer-Veger N, Buunk A . Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines. Eur J Hum Genet. 2019; 28(4):508-517. PMC: 7080718. DOI: 10.1038/s41431-019-0540-0. View

20.

Swen J, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee A, Mulder H . Pharmacogenetics: from bench to byte--an update of guidelines. Clin Pharmacol Ther. 2011; 89(5):662-73. DOI: 10.1038/clpt.2011.34. View